Decipher Labs Ltd.
Snapshot View

37.60 0.00

03 August 2021, 04:00:00 P.M.
Volume: 3,036

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.combatdrugs.in
Financial Indicators
Market Cap 38.03 Cr.
Earnings per share (EPS) 1.39 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 27.10 Trailing Twelve Months Ending 2021-03
Industry PE 32.95 Trailing Twelve Months Ending 2021-03
Book Value / Share 13.55 Trailing Twelve Months Ending 2021-03
Price to Book Value 2.78 Calculated using Price: 37.65
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 1.01 Cr. 10,100,000 Shares
FaceValue 10
Company Profile

Combat is a professionally managed, well established public limited company, engaged in the manufacture & marketing of Pharmaceutical Formulations since its incorporation in 1986. The company has been marketing its branded formulations and entering into agreements with various companies for custom manufacturing and has grown to be known as a quality provider.

During the years of operations, the products of the company have been well accepted by the Trade and Medical Fraternity across India.Playing a key role in promoting and sustaining development in the vital field of Pharmaceuticals, Combat Drugs boasts of quality fixed dosage formulations manufactured in multiple locations with GMP & WHO cGMP certification and certified through a well designed Quality Assurance Program, approved by regulatory authorities in India.

Quality, Efficacy & Service are the three key words in the company’s motto in providing succor to the ailing Humanity by producing high quality medicines at an affordable cost for combating life threatening Diseases and improving the global standards of health. In order to achieve this objective, the company lays emphasis on implementing total Quality Assurance of its formulations by inculcating the principles of Good Manufacturing Practices among its staff members at all levels.

Some of the Key Highlights in making Combat a preferred supplier to the consumer as well as the medical fraternity are:

• An Un-compromised commitment towards quality.
• Competitively priced solutions.
• Technologically strong and totally self-reliant.
• Vast experience and technical know-how
•  The right product-mix for sustained future growth.
•  Well known brands with high market penetration.
•  Extensive distribution network with an all India presence.

Busines area of the company:

The company is engaged in the manufacture & marketing of Pharmaceutical Formulations.

Products:

Combat is engaged in the manufacturing and marketing of its branded Pharmaceutical Formulations in the following mentioned forms and methods:

a) Solid dosage forms: Unit dose form(Tablets, Capsules): Single Ingredient / Multi Ingredient, Plain, Film, Sugar & Enteric Coated, Patent & Proprietary Tablets of various sizes; shapes and colors. And Single and Multi ingredient capsules.

b) Liquid dosage forms: Liquid Orals as Single Ingredient and Multi Ingredient in various measures as desired by the buyer.

c) Ointments: Various Combinations of Ointments
   

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
1 Week
+5.03%
1 Month
+10.75%
3 Month
+19.18%
6 Month
-3.22%
1 Year
+74.07%
2 Year
+38.75%
5 Year
+705.14%
3 years 2018-03 2019-03 2020-03
Return on Equity (%) 8.60 17.45 14.59
Return on Capital Employed (%) 8.10 17.95 16.97
Return on Assets (%) 6.16 8.71 5.08

Balance Sheet View Details

Particulars 3 years 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 2 3 13
Non Curr. Liab. 1
Curr. Liab. 1 4 23
Minority Int.
Equity & Liab. 3 6 37
Non Curr. Assets 0 13
Curr. Assets 3 6 24
Misc. Exp. not W/O
Total Assets 3 6 37

Profit Loss View Details

Particulars 3 years 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 1 8 24
Other Income 0 0
Total Income 1 8 24
Total Expenditure -1 -8 -21
PBIDT 0 0 3
Interest 0 -1
Depreciation -1
Taxation 0 0
Exceptional Items
PAT 0 0 1

Cash Flow View Details

Particulars 3 years 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 0 0 -15
Cash Fr. Inv. 0 0
Cash Fr. Finan. 0 0 18
Net Change 0 0 3
Cash & Cash Eqvt 0 0 3

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 58.00 58.00 45.94 45.94 45.94 45.94 45.94 45.94 45.94
Public 42.00 42.00 54.06 54.06 54.06 54.06 54.06 54.06 54.06
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Wed, 14 Jul 2021
Shareholding for the Period Ended June 30 2021
Decipher Labs Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here
Wed, 07 Jul 2021
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Compliance Certificate for the Quarter under Regulation 74(5)
Mon, 05 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0000
Name of the Signatory :- Kumar Raghavan
Designation :- Company Secretary and Compliance Officer

Technical Scans View Details

Tue, 03 Aug 2021
CCI Crossed Above 100 CCI Crossed Above 100
CCI Overbought Zone CCI Overbought Zone
Mon, 02 Aug 2021
High Delivery Percentage High Delivery Percentage
Close Crossing Last Month Close From Below Close Crossing Last Month Close From Below
Closing Above Previous High Closing Above Previous High

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 190,711.14 794.85 +2.6%
Divi's Laboratories Ltd. 132,945.34 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. 78,541.95 4,721.20 +0.4%
Cipla Ltd. 74,795.92 927.25 +0.6%
Cadila Healthcare Ltd. 60,600.44 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. 58,835.96 4,076.05 +0.7%
Piramal Enterprises Ltd. 56,942.27 2,507.65 +0.7%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 31.77 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2021-03 67.00 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.21 4,721.20 +0.4%
Cipla Ltd. Consolidated 2021-03 31.10 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 28.40 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 391.30 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 42.74 2,507.65 +0.7%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 3.98 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2021-03 14.30 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.39 4,721.20 +0.4%
Cipla Ltd. Consolidated 2021-03 4.09 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 4.66 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.80 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 1.66 2,507.65 +0.7%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,721.20 +0.4%
Cipla Ltd. Consolidated 2020-03 0.18 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 2,507.65 +0.7%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,721.20 +0.4%
Cipla Ltd. Consolidated 2020-03 10.09 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 2,507.65 +0.7%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,721.20 +0.4%
Cipla Ltd. Consolidated 2020-03 12.53 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 10.03 2,507.65 +0.7%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,721.20 +0.4%
Cipla Ltd. Consolidated 2020-03 19,159.59 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 2,507.65 +0.7%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,721.20 +0.4%
Cipla Ltd. Consolidated 2020-03 2,401.30 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 2,507.65 +0.7%